Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. It has collaboration agreements with Biogen MA, Inc., Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation. The company was founded in 1999 and is headquartered in Alachua, Florida.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AGTC
Previous Symbol
CUSIPN/A
Phone386-462-2204
Debt
Debt-to-Equity RatioN/A
Current Ratio4.32
Quick Ratio4.32
Price-To-Earnings
Trailing P/E Ratio-3.03
Forward P/E Ratio-2.83
P/E GrowthN/A
Sales & Book Value
Annual Sales$24.19 million
Price / Sales2.65
Cash FlowN/A
Price / Cash FlowN/A
Book Value$5.48 per share
Price / Book0.65
Profitability
EPS (Most Recent Fiscal Year)($1.18)
Net Income$-21,300,000.00
Net Margins-67.02%
Return on Equity-18.97%
Return on Assets-15.19%
Miscellaneous
Employees78
Outstanding Shares18,130,000
Market Cap$110.78 million
OptionableOptionable
Applied Genetic Technologies (NASDAQ:AGTC) Frequently Asked Questions
What is Applied Genetic Technologies' stock symbol?
Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC."
How were Applied Genetic Technologies' earnings last quarter?
Applied Genetic Technologies Corp (NASDAQ:AGTC) released its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.50) by $0.57. The biotechnology company earned $14.03 million during the quarter, compared to the consensus estimate of $2.90 million. Applied Genetic Technologies had a negative net margin of 67.02% and a negative return on equity of 18.97%. View Applied Genetic Technologies' Earnings History.
When is Applied Genetic Technologies' next earnings date?
What price target have analysts set for AGTC?
6 analysts have issued 1-year price targets for Applied Genetic Technologies' shares. Their forecasts range from $5.00 to $15.00. On average, they expect Applied Genetic Technologies' stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 119.8% from the stock's current price. View Analyst Price Targets for Applied Genetic Technologies.
What is the consensus analysts' recommendation for Applied Genetic Technologies?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Applied Genetic Technologies.
Has Applied Genetic Technologies been receiving favorable news coverage?
News articles about AGTC stock have trended somewhat positive this week, InfoTrie reports. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Applied Genetic Technologies earned a news impact score of 2.0 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term.
Who are some of Applied Genetic Technologies' key competitors?
Some companies that are related to Applied Genetic Technologies include Replimune Group (REPL), PDL BioPharma (PDLI), Translate Bio (TBIO), Mesoblast (MESO), Cellular Biomedicine Group (CBMG), CASI Pharmaceuticals (CASI), La Jolla Pharmaceutical (LJPC), Voyager Therapeutics (VYGR), Nightstar Therapeutics (NITE), Krystal Biotech (KRYS), MeiraGTx (MGTX), Agenus (AGEN), LogicBio Therapeutics (LOGC), Gamida Cell (GMDA) and Surface Oncology (SURF).
Who are Applied Genetic Technologies' key executives?
Applied Genetic Technologies' management team includes the folowing people:
- Ms. Susan B. Washer, Pres, CEO & Director (Age 57)
- Mr. William A. Sullivan, Chief Financial Officer (Age 47)
- Dr. Matthew Feinsod, Interim Chief Medical Officer (Age 47)
- Dr. Nicholas Muzyczka, Co-Founder
- Dr. Barry J. Byrne, Co-Founder
Who are Applied Genetic Technologies' major shareholders?
Applied Genetic Technologies' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (4.51%), Renaissance Technologies LLC (3.90%), Wells Fargo & Company MN (1.19%), Point72 Asset Management L.P. (0.93%), Man Group plc (0.72%) and Bridgeway Capital Management Inc. (0.70%). View Institutional Ownership Trends for Applied Genetic Technologies.
Which institutional investors are selling Applied Genetic Technologies stock?
Which institutional investors are buying Applied Genetic Technologies stock?
How do I buy shares of Applied Genetic Technologies?
Shares of AGTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Applied Genetic Technologies' stock price today?
One share of AGTC stock can currently be purchased for approximately $3.64.
How big of a company is Applied Genetic Technologies?
Applied Genetic Technologies has a market capitalization of $110.78 million and generates $24.19 million in revenue each year. The biotechnology company earns $-21,300,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. Applied Genetic Technologies employs 78 workers across the globe.
What is Applied Genetic Technologies' official website?
How can I contact Applied Genetic Technologies?
Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The biotechnology company can be reached via phone at 386-462-2204.
MarketBeat Community Rating for Applied Genetic Technologies (NASDAQ AGTC)
MarketBeat's community ratings are surveys of what our community members think about Applied Genetic Technologies and other stocks. Vote "Outperform" if you believe AGTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
